A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with breast cancer lose weight.

Recruiting now. Registry record last updated July 22, 2026.

Who can join: Adults 18+, women only, have obesity, BMI 27.5+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Weill Medical College of Cornell UniversityDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 30

What this study is for

Primary condition: Obesity (Disorder). Also studied in: Breast Cancer.

Full scientific study title: Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors.

Who can join

Age18 and upSexFemaleBMI27.5 or higher

Adults 18+, women only, have obesity, BMI 27.5+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Biologically female
Age ≥ 18
Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry
Postmenopausal as defined by one or more of the following
Age ≥60 years

Key exclusion criteria

Stage IV breast cancer
Concomitant use of CDK inhibitors
Concomitant use of antiHER2 therapy
The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications
Other active malignancy requiring treatment

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

New York1 site

Weill Cornell Medicine
New York, New York
Sarah Schmitz, MD646-962-2111hls9007@med.cornell.edu

Follow this trial

We email you if NCT07257484 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: June 8, 2026. Expected completion: February 25, 2028. Last updated on ClinicalTrials.gov: July 22, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.